ストックスクリーナーアプリを入手
11.23
0.36%
0.04
アフターアワーズ：
11.23
前日終値:
$11.19
開ける：
$11.27
24時間の取引高:
480.47K
Relative Volume:
1.12
時価総額：
$222.26M
収益：
$244.06M
当期純損益:
$87.01M
株価収益率:
6.1659
EPS:
1.8213
ネットキャッシュフロー:
$105.95M
1週間 パフォーマンス:
+13.32%
1か月 パフォーマンス:
-2.43%
6か月 パフォーマンス:
-35.83%
1年 パフォーマンス:
-22.92%
1日の値動き範囲:
$10.84
$11.36
1週間の範囲:
$9.98
$11.48
52週間の値動き範囲:
$9.79
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.23 | 221.47M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies - The Globe and Mail
Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - The Globe and Mail
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - The Globe and Mail
Keros Therapeutics (KROS) Q1 2026 Disappoints — EPS $-1.21 Below $-1.04 ViewsQuarterly Earnings Report - Newser
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN
Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans - Streetwise Reports
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles - Streetwise Reports
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Keros Therapeutics, Inc.common stock (NQ: KROS - The Chronicle-Journal
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $20 to $20 - Moomoo
Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail
Keros Therapeutics Reports Q1 2026 Financial Results: Net Loss, Cash Position, and R&D Updates - Minichart
Keros Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Keros Therapeutics (KROS) swings to Q1 2026 loss as Takeda revenue steps down - Stock Titan
Keros Therapeutics 1Q 2026: Revenue $367K, EPS ($1.21) — 10-Q Summary - TradingView
Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss - Stock Titan
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results - marketscreener.com
Keros (NASDAQ: KROS) swings to Q1 2026 loss as Takeda license boost fades - Stock Titan
KROS stock: Does the Takeda deal lower dilution risk in 2026? - MSN
TradingKey - TradingKey
Top iBio (IBIO) Competitors 2026 - MarketBeat
KROS (Keros Therapeutics) Q4 earnings miss: EPS $-0.86 vs estimate $-0.64, stock slides 1.19%.Decline Risk - newser.com
What Keros Therapeutics (KROS) does that makes it resilient (Flat) 2026-05-06Top Analyst Picks - newser.com
(KROS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirsc - Barchart.com
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday - MarketBeat
Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset - MSN
Responsive Playbooks and the KROS Inflection - Stock Traders Daily
KROS|Keros Therapeutics Inc|Price:11.510|Chg%:-0.05 - TradingKey
ADAR1 Capital Management urges Keros Therapeutics for board change - MSN
Keros Therapeutics (KROS) Business Update | Q4 2025: Earnings UnderperformShared Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
Keros Therapeutics Inc (KROS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Apr 15 '26 |
Buy |
11.70 |
1,000 |
11,700 |
8,450 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 02 '26 |
Option Exercise |
0.30 |
55,000 |
16,500 |
440,708 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):